SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Brown JR, DuBois RN. Cyclooxygenase as a target in lung cancer. Clin Cancer Res. 2004; 10: 4266s-4269s.
  • 2
    Dannenberg AJ, Lippman SM, Mann JR, Subbaramaiah K, DuBois RN. Cyclooxygenase-2 and epidermal growth factor receptor: pharmacologic targets for chemoprevention. J Clin Oncol. 2005; 23: 254-266.
  • 3
    Mok TS, Wu YL, Thongprasert S, et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med. 2009; 361: 947-957.
  • 4
    Pirker R, Pereira JR, Szczesna A, et al. Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial. Lancet. 2009; 373: 1525-1531.
  • 5
    Rosell R, Moran T, Queralt C, et al. Screening for epidermal growth factor receptor mutations in lung cancer. N Engl J Med. 2009; 361: 958-967.
  • 6
    Shepherd FA, Rodrigues Pereira J, Ciuleanu T, et al. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med. 2005; 353: 123-132.
  • 7
    Edelman MJ, Watson D, Wang X, et al. Eicosanoid modulation in advanced lung cancer: cyclooxygenase-2 expression is a positive predictive factor for celecoxib + chemotherapy—Cancer and Leukemia Group B Trial 30203. J Clin Oncol. 2008; 26: 848-855.
  • 8
    Gadgeel SM, Ali S, Philip PA, Ahmed F, Wozniak A, Sarkar FH. Response to dual blockade of epidermal growth factor receptor (EGFR) and cycloxygenase-2 in nonsmall cell lung cancer may be dependent on the EGFR mutational status of the tumor. Cancer. 2007; 110: 2775-2784.
  • 9
    Lippman SM, Gibson N, Subbaramaiah K, Dannenberg AJ. Combined targeting of the epidermal growth factor receptor and cyclooxygenase-2 pathways. Clin Cancer Res. 2005; 11: 6097-6099.
  • 10
    Zhang X, Chen ZG, Choe MS, Lin Y, Sun SY, Wieand HS, et al. Tumor growth inhibition by simultaneously blocking epidermal growth factor receptor and cyclooxygenase-2 in a xenograft model. Clin Cancer Res. 2005; 11: 6261-6269.
  • 11
    Krysan K, Lee JM, Dohadwala M, Gardner BK, Reckamp KL, Garon E, et al. Inflammation, epithelial to mesenchymal transition, and epidermal growth factor receptor tyrosine kinase inhibitor resistance. J Thorac Oncol. 2008; 3: 107-110.
  • 12
    Lawhon TL, Zaknoen SL, Wong AJ, Meshaw KR, Johnson RK. Activity of TG01, a selective cox-2 inhibitor, alone and in combination with docetaxel in human non–small cell lung carcinoma xenografts. Proc Am Assoc Cancer Res. 2008: Abstract 5663.
  • 13
    Senzaki M, Ishida S, Yada A, et al. CS-706, a novel cyclooxygenase-2 selective inhibitor, prolonged the survival of tumor-bearing mice when treated alone or in combination with anti-tumor chemotherapeutic agents. Int J Cancer. 2008; 122: 1384-1390.
  • 14
    Murphey LJ, Williams MK, Sanchez SC, et al. Quantification of the major urinary metabolite of PGE2 by a liquid chromatographic/mass spectrometric assay: determination of cyclooxygenase-specific PGE2 synthesis in healthy humans and those with lung cancer. Anal Biochem. 2004; 334: 266-275.
  • 15
    Csiki I, Morrow JD, Sandler A, et al. Targeting cyclooxygenase-2 in recurrent non–small cell lung cancer: a phase II trial of celecoxib and docetaxel. Clin Cancer Res. 2005; 11: 6634-6640.
  • 16
    Johnson JC, Schmidt CR, Shrubsole MJ, et al. Urine PGE-M: A metabolite of prostaglandin E2 as a potential biomarker of advanced colorectal neoplasia. Clin Gastroenterol Hepatol. 2006; 4: 1358-1365.
  • 17
    Mutter R, Lu B, Carbone DP, et al. A phase II study of celecoxib in combination with paclitaxel, carboplatin, and radiotherapy for patients with inoperable stage IIIA/B non–small cell lung cancer. Clin Cancer Res. 2009; 15: 2158-2165.
  • 18
    Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst. 2000; 92: 205-216.
  • 19
    Fidler MJ, Argiris A, Patel JD, et al. The potential predictive value of cyclooxygenase-2 expression and increased risk of gastrointestinal hemorrhage in advanced non–small cell lung cancer patients treated with erlotinib and celecoxib. Clin Cancer Res. 2008; 14: 2088-2094.
  • 20
    Gadgeel SM, Wozniak A, Ruckdeschel JC, et al. Phase II study of docetaxel and celecoxib, a cyclooxygenase-2 inhibitor, in elderly or poor performance status (PS2) patients with advanced non–small cell lung cancer. J Thorac Oncol. 2008; 3: 1293-1300.
  • 21
    Schneider BJ, Kalemkerian GP, Kraut MJ, et al. Phase II study of celecoxib and docetaxel in non–small cell lung cancer (NSCLC) patients with progression after platinum-based therapy. J Thorac Oncol. 2008; 3: 1454-1459.
  • 22
    Agarwala A, Fisher W, Bruetman D, et al. Gefitinib plus celecoxib in chemotherapy-naive patients with stage IIIB/IV non–small cell lung cancer: a phase II study from the Hoosier Oncology Group. J Thorac Oncol. 2008; 3: 374-379.
  • 23
    Gadgeel SM, Ruckdeschel JC, Heath EI, Heilbrun LK, Venkatramanamoorthy R, Wozniak A. Phase II study of gefitinib, an epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI), and celecoxib, a cyclooxygenase-2 (COX-2) inhibitor, in patients with platinum refractory non–small cell lung cancer (NSCLC). J Thorac Oncol. 2007; 2: 299-305.
  • 24
    O'Byrne KJ, Danson S, Dunlop D, et al. Combination therapy with gefitinib and rofecoxib in patients with platinum-pretreated relapsed non small-cell lung cancer. J Clin Oncol. 2007; 25: 3266-3273.
  • 25
    Krysan K, Reckamp KL, Dalwadi H, et al. Prostaglandin E2 activates mitogen-activated protein kinase/Erk pathway signaling and cell proliferation in non–small cell lung cancer cells in an epidermal growth factor receptor-independent manner. Cancer Res. 2005; 65: 6275-6281.